Engineered PCV2 VLPs for Antigen Delivery: A Platform for Next-Generation Veterinary Vaccines

Area of Science:

• Veterinary Virology
• Nanotechnology
• Immunology

Background:

• Porcine circovirus type 2 (PCV2) capsid (Cap) protein self-assembles into T=1 icosahedral virus-like particles (VLPs).
• These VLPs mimic native virion architecture, presenting antigens in an ordered array for strong immunogenicity.
• VLPs elicit both humoral and cellular immune responses, making them attractive vaccine candidates.

Purpose of the Study:

• To review the structural basis of PCV2 VLPs as an antigen display platform.
• To detail molecular engineering strategies for enhancing VLP immunogenicity.
• To analyze the impact of expression systems on chimeric VLP production and efficacy.

Main Methods:

• Structural analysis of PCV2 VLP assembly and antigen presentation.
• Molecular engineering targeting N-terminal, surface loops, and C-terminal sites.
• Evaluation of different expression systems for VLP production.
• Analysis of chimeric VLP immunogenicity.

Main Results:

• PCV2 VLPs can be engineered at specific sites for targeted immune responses (CD8+ T-cell activation, B-cell epitope presentation).
• Chimeric VLPs demonstrate potential for modular fusion of protein domains.
• Expression systems influence VLP production yield and immunogenicity.
• Challenges remain in particle stability and large-scale production.

Conclusions:

• PCV2 VLPs represent a versatile platform for developing veterinary vaccines with balanced and potent immunity.
• Structure-guided design advances are crucial for optimizing VLP-based vaccines.
• Further integration of rational design and in-species evaluation is needed for multivalent vaccine development.